Relationship of the pulmonary disease severity scoring with thromboembolic complications in COVID-19

Ali H. Elmokadem1,2 · Dalia Bayoumi1 · Ahmed El-Morsy1 · Ahmed Ehab3,4 · Sherif A. Abo-Hedibah2,5

Received: 2 August 2021 / Accepted: 8 November 2021 / Published online: 20 November 2021
© American Society of Emergency Radiology 2021

Abstract

Purpose To correlate thromboembolic (TE) complications secondary to COVID-19 with the extent of the pulmonary parenchymal disease using CT severity scores and other comorbidities.

Methods In total, 185 patients with COVID-19 and suspected thromboembolic complications were classified into two groups based on the presence or absence of thromboembolic complications. Thromboembolic complications were categorized based on location. Chest CT severity scoring system was used to assess the pulmonary parenchymal disease severity in all patients. Based into severity scores, patients were categorized into three groups (mild, moderate, and severe disease).

Results The final study cohort consisted of 171 patients (99 male and 72 female) after excluding 14 patients with non-diagnostic CT pulmonary angiography. The TE group included 53 patients with a mean age of 55.1 ± 7.1, while the non-TE group included 118 patients with a mean age of 52.9 ± 10.8. Patients with BMI > 30 kg/m² or having a history of smoking and HTN were found more frequently in the TE group (p < 0.05). Patients admitted to ICU were significantly higher in the TE group (p < 0.001). There was statistically significant difference (p = 0.002) in chest CT-SS between the TE group (22.8 ± 11.4) and non-TE group (17.6 ± 10.7). The percentage of severe parenchymal disease in the TE group was significantly higher compared to the non-TE group (p < 0.05). Severe parenchymal disease, BMI > 30 kg/m², smoking, and HTN had a higher and more significant odds ratio for developing TE complications.

Conclusion The present data suggest that severe pulmonary parenchymal disease secondary to COVID-19 is associated with a higher incidence of thromboembolic complications.

Keywords COVID-19 · SARS-CoV-2 · Coronavirus · Thrombosis · Embolism · Ischemia

Abbreviations

COVID-19 Coronavirus disease 2019
TE Thromboembolic
SARS-CoV-2 Acute respiratory syndrome coronavirus-2
MERS Middle East respiratory syndrome
SARS-CoV-1 Severe acute respiratory syndrome coronavirus-1
RT-PCR Reverse transcriptase-polymerase chain reaction

Key Points
• Assessment of pulmonary parenchymal disease of COVID-19 using chest CT severity scores.
• The greater the CT severity score, The higher incidence of thromboembolic complications in COVID-19 patients.
• Comorbidities like BMI > 30 kg/m², Smoking, and HTN had a higher and more significant odds ratio for developing TE complications in COVID-19 patients

Ali H. Elmokadem
mokadem83@yahoo.com
Dalia Bayoumi
dalibayoumi1982@gmail.com
Ahmed El-Morsy
dr.a.elmorsy@gmail.com
Ahmed Ehab
dra.ehab@gmail.com
Sherif A. Abo-Hedibah
sherifabohe dibah@gmail.com

1 Department of Radiology, Mansoura University, Elgomhoria St., Mansoura 35516, Egypt
2 Department of Radiology, Farwaniya Hospital, Kuwait City, Kuwait
3 Pulmonary Medicine Department, Mansoura University, Elgomhoria St., Mansoura, Egypt
4 Pulmonary Medicine Department, Loewenstein Lung Center, Löwenstein, Germany
5 Department of Radiology, Cairo University, Giza, Egypt
Introduction

Since December 2019, a new type of coronavirus was isolated from the lower respiratory tract samples. It was named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1] and later as coronavirus disease 2019 (COVID-19) [2–4]. COVID-19 is a mysterious disease primarily affecting the lungs with a wide range of clinical presentations ranging from asymptomatic illness to deadly severe respiratory disease [5, 6]. In addition to pulmonary disease, COVID-19 may cause a wide spectrum of systemic diseases due to the involvement of different organs by the virus or to complications directly or indirectly related to this infection. Causes of death in COVID-19 disease are numerous and overlapping, including uncontrolled immunological response known as cytokine storm and thromboembolic (TE) events, which necessitates ICU admission. Early studies investigated thromboembolic complications, and surprisingly they were not confined to the lungs with elevated serum thrombogenic proteins such as D-dimer but also seen in the cerebral, abdominal, and peripheral vessels [7]. Similarly, other hemostatic abnormalities were reported in some COVID-19 patients, including mild thrombocytopenia, hyperfibrinogenaemia, increased clot strength, which all indicate a pro-coagulant pattern of COVID-19 [8]. Several postulates have been put forward to explain the higher incidence of thromboembolic events in COVID-19 patients. There are two major theories; progressive endothelial thrombo-inflammatory syndrome or COVID-19 endothelitis with resultant microangiopathy and the high level of circulating cytokines and inflammatory mediators. Both factors induce an abnormal hypercoagulable state with disseminated thrombosis, resulting in multi-organ failure and death [9].

Evidence is accumulating suggesting different mechanisms that have a role in morbidity and death associated with thromboembolic complications of COVID-19. Even in patients taking therapeutic anticoagulation, clinical and postmortem investigations have demonstrated a significant prevalence of venous and arterial thromboembolic events, including pulmonary embolism [10]. These data have led to recommendations for greater anticoagulation goals, although it is still unclear which individuals are at higher risk and need prophylactic anticoagulation. Even though fibrinogen and D-dimer levels are typically raised, neither of these parameters accurately identifies people at risk of thromboembolic consequences [11]. So yet, the specific pathomechanisms which lead to the prothrombotic status in these patients remain unclear.

Chest imaging using CT plays a significant role in diagnosis assessing parenchymal severity and follow-up of COVID-19. On chest CT, manifestations resemble those seen in viral pneumonia, with multifocal ground-glass opacities and consolidation in a peripheral distribution being the most common findings [12, 13]. The main aim of our study was to correlate COVID-19 thromboembolic events with the extent of pulmonary parenchymal involvement using CT severity scores. We hypothesized that the greater the CT severity scores, the higher incidence of thromboembolic complications. The secondary aim was to correlate thromboembolic events and other comorbidities.

Materials and methods

Study population

The local institutional review board approved this retrospective study, and a waiver of the consent of medical record review was received. We studied the patients diagnosed with COVID-19 by RT-PCR test and were suspected of having thromboembolic complications. Indication of imaging assessment of TE complications was acute shortness of breath, chest pain or hemoptysis for suspected PE, focal weakness or persistent headache for suspected intracranial thrombosis, severe abdominal pain for suspected visceral ischemia, or signs of peripheral ischemia. Patients with a history of lung malignancy, interstitial lung disease, lobectomy, and tuberculosis were excluded to avoid possible bias because of overlapped pathology. All patients underwent cross-sectional imaging studies to diagnose suspected thromboembolic events. Pulmonary parenchymal severity was scored from chest CT and radiographs that were closest from the date to the imaging study requested to assess thromboembolic complications. Patient demographic, clinical, laboratory, and outcome data were extracted from electronic medical records.

The study included 185 patients and was classified into two groups based on the presence or absence of thromboembolic events. The final study cohort consisted of 171 patients (99 male and 72 female) after excluding 14 patients with non-diagnostic CT pulmonary angiography. The TE group consisted of 53 patients with a mean age of 55.1 ± 7.1, while the non-TE group consisted of 118 patients with a mean age of 52.9 ± 10.8.
Thromboembolic complications

Patients were categorized based on the location of suspected TE complications (pulmonary \( n = 116 \), cerebral \( n = 33 \), visceral \( n = 30 \), and peripheral \( n = 6 \)). The study flow chart is illustrated in Fig. 1. CT pulmonary angiography was used to assess the extent and site of pulmonary embolism and signs of right ventricular strain. CT and/or MRI were used to assess the site, distribution, and possibility of hemorrhagic nature or transformation of cerebral infarctions. CT angiography was used to assess visceral and peripheral ischemia.

Pulmonary parenchymal disease severity scoring

Chest CT was used to assess the pulmonary parenchymal severity scores in all patients and chest radiographs in 24 patients. CT images and radiographs were independently reviewed by two radiologists with more than 5 and 8 years of experience in thoracic imaging. Reviewers were blinded from the clinical data and the presence of thromboembolic complications. They were requested to assess the pulmonary window of chest CT scans only. A consensus was reached by a chest radiologist with more than 10 years of experience where there was a disagreement.

Chest CT severity score (CT-SS)

The CT-SS is an adaptation of a method used before to describe GGO, interstitial opacity, and air trapping, which was correlated with clinical and laboratory parameters in patients after SARS [14, 15]. The 18 segments of both lungs are divided into 20 regions. The posterior apical segment of the left upper lobe is divided into apical and posterior segmental regions, and the anteromedial basal segment of the left lower lobe is subdivided into anterior and basal segmental regions. The lung attenuations in all 20 lung regions are subjectively evaluated on chest CT and given a score of 0, 1, or 2 if the parenchymal opacification involved 0%, less than 50%, or equal or more than 50% of each region, respectively. The CT-SS is defined as the sum of each score in the 20 lung segment regions, ranging from 0 to 40 points. We have classified all the CT studies of our patients into three groups according to their total CT-SS, as follows: (i) mild disease: scores from 0 to 13, (ii) moderate disease: scores from 14 to 27, (iii) severe disease: scores from 28 to 40.

Fig. 1 Flow chart of the study population
Chest CT imaging was done on a 256-detector CT scanner (Revolution; GE). CT scan parameters: 120 KVP, 350 mAs; rotation time: 0.5 s; pitch: 1.0; section thickness: 5 mm; intersection space: 5 mm; additional reconstruction with sharp convolution kernel; and a slice thickness of 1.5 mm. Scans were reviewed at a window width and level of 1000 to 2000 HU and −700 to −500 HU, respectively, to assess the lung parenchyma. Reviewers were asked to assess the presence of CT findings associated with COVID-19.

### Results

#### Patients

Out of 171 patients included in this study with positive RT-PCR tests for SARS-CoV-2, only 53 patients (31%) had positive findings of thromboembolic complications. There was no significant difference in the age and gender distribution between TE and non-TE groups. Patients with a body mass index (BMI) > 30 kg/m² were found more frequently in the TE group compared to the non-TE group (58.5% vs. 32.2%, $p = 0.04$). History of smoking and HTN was more common among patients in the TE group ($p < 0.05$). Dyslipidemia was statistically more in the non-TE group than the TE group ($p < 0.001$).

#### Table 1 Patients’ demographics, comorbidities, and ICU admission in both groups

| Age (mean± SD) | Thromboembolic disease | p-value |
|---------------|------------------------|---------|
| Yes (n=53)    | 55.1± 7.1              | 52.9±10.8 | 0.27 |
| No (n=118)    | 29 (54.7%)             | 70 (59.3%) | 0.7 |
| Male          | 24 (45.3%)             | 48 (40.7%) |          |
| Female        | 31 (58.5%)             | 38 (32.2%) | 0.040* |
| BMI > 30      | 29 (54.7%)             | 36 (30.5%) | 0.049* |
| Smoking       | 34 (64.1%)             | 42 (35.6%) | 0.036* |
| DM            | 32 (41.5%)             | 43 (36.4%) | 0.67 |
| Previous PE/DVT | 7 (13.2%) | 12 (10.2%) | 0.60 |
| Dyslipidemia  | 9 (16.9%)              | 44 (37.3%) | 0.046* |
| CKD           | 6 (11.3%)              | 10 (8.5%) | 0.59 |
| Malignancy    | 4 (7.5%)               | 12 (10.2%) | 0.61 |
| Mild          | 9 (17%)                | 44 (37.3%) | 0.046* |
| Moderate      | 20 (37.7%)             | 46 (39%) | 0.91 |
| Severe        | 24 (45.3%)             | 28 (23.7%) | 0.043* |
| ICU admission | 41 (77.4%)             | 30 (25.4%) | <0.001* |
| Mortality     | 14 (26.4%)             | 12 (10.2%) | 0.022* |

Data expression [test of significance]: N (%) [chi-square or *Fisher’s exact test] or mean± SD

![Fig. 2](image_url) PE in a 65-year-old male patient with confirmed diagnosis of COVID-19. **a, b** Coronal CT chest in pulmonary window shows bilateral GGO and posteriorly located consolidations, CT-SS = 29. **c** CT pulmonary angiography shows multiple segmental and subsegmental pulmonary embolism.
(16.9% vs. 37.3%, $p = 0.046$). There was no significant difference in the history of DM, CKD, and presence of malignancy as well as previous PE or DVT between both groups. Patients admitted to ICU were significantly more in the TE group (77.4% vs. 25.4%, $p < 0.001$). Similarly, mortality was greater in the TE group (26.4% vs. 10.2%, $p = 0.02$).

Comparison between patients’ data among TE-positive and TE-negative groups is demonstrated in Table 1.

### TE complications

Pulmonary embolism was detected in 26/102 (25.5%) of study cases (Fig. 2), while D-dimer was elevated in 79/102 (77.5%) of study cases. There was a significant difference ($p = 0.001$) between the D-dimer level in the positive group (6863 ± 714) and the negative group (3091 ± 455). The location of the pulmonary embolism was recorded according to the most proximal embolus. Distribution was as follows: 23.1% (6/26) subsegmental PE, 34.6% (9/26) segmental PE, 15.4% (4/26) lobar PE, 23.1% (6/26) central PE, and 3.8%
Fig. 4  Upper limb ischemia in a 36-year-old male patient with confirmed diagnosis of COVID-19. a Axial CT chest in pulmonary window shows bilateral GGO and posteriorly located consolidations, CT-SS = 15. b CT pulmonary angiography shows thrombi filling the right and left pulmonary arteries. c Left upper limb coronal and MIP CTA show totally thrombosed brachial artery with distal collateral filling

Fig. 5  Dural sinus thrombosis in a 38-year-old male patient who presented by persistent head and confirmed diagnosis of COVID-19. a Axial CECT shows right side focal gyral enhancement secondary to venous congestion. b Axial CTV shows empty delta sign secondary to thrombosed superior sagittal sinus. c Sagittal CTV shows multiple filling defects in the superior sagittal and straight sinuses. d Axial FLAIR image shows right side cortical vein of high signal intensity denoting thrombosis. e TOF MRV demonstrates absent flow signal in the right vein of Trolrad, proximal part of the left transverse sinus, and filling defect at the right sigmoid sinus. f Sagittal T2 image shows abnormal signal intensity of the superior sagittal and straight sinuses. Chest CT was unremarkable and CT-SS was equal to 0
(1/26) saddle PE. CT signs of right heart strain as the deviation of the interventricular septum and increased ventricular ratio were reported in 19.2% (5/26) of patients. Three patients had TE manifestations in multiple sites and they were included in PE group only and were not included in other groups. One patient had cerebral, renal, and splenic infarctions, signs of mesenteric ischemia, thrombosed infra-renal aorta, and the arterial tree of both lower limbs (Fig. 3). The other two cases were presented by peripheral limb ischemia and pulmonary embolism (occluded brachial artery (Fig. 4) and the popliteal artery).

Intracranial TE complications were suspected in 33 patients. All cases were assessed initially by NCCT. Fourteen patients were examined by CTA and ten patients underwent MRI and time of flight MRA or MRV. The overall incidence of TE complications was 45.4% (15/33), 3 of them were dural sinus thrombosis (Fig. 5) while the rest were cerebral infarctions (Fig. 6). Distribution of cerebral infarction was as follows: lobar infarction in 41.6% (5/12), multiple locations in 33.3% (4/12), cerebellar infarction in 16.6% (2/12), and lacunar infarct in 8.3% (1/12). Hemorrhagic component was detected in four patients (36.4%). CTA detected arterial occlusion in three patients (27.3%) and MRA in two patients (18.2%).

Abdominal CT and CTA were done to investigate abdominal pain for 30 patients with COVID-19. Positive findings related to TE events were detected in 26.6% (8/30). Seven patients showed signs of mesenteric ischemia with variable degrees of mesenteric artery occlusion (Fig. 7). One patient had partial splenic and hepatic artery thrombosis with subsequent splenic infarctions (Fig. 8). Peripheral CTA was done to rule out arterial ischemia in 6 patients. Arterial occlusion was detected in 66.6% (4/6); three of them had (75%) thrombosed lower limb arteries and only one upper limb arterial thrombosis.

**Pulmonary parenchymal disease severity scoring**

Chest CT was used to assess the severity of pulmonary parenchymal disease in all patients. Severe parenchymal disease in both groups was reported by chest CT in 30.4% (52/171), while moderate parenchymal disease was found in 38.6% (66/171). There was statistically significant difference (p = 0.002) in chest CT-SS between the TE group (22.8 ± 11.4) and non-TE group (17.6 ± 10.7). Additionally, the percentage of severe parenchymal disease in the TE group was significantly higher compared to the non-TE group (45.3% vs. 23.7%, p = 0.04). The interobserver
agreement was excellent for chest CT-SS (kappa = 0.874). There was no significant difference in different imaging features detected by chest CT in both groups. Table 2 demonstrates the chest CT-SS and imaging features in both groups.

**Univariate analysis**

A univariate analysis was developed to predict TE complications and odds ratios for significant results. Severe parenchymal disease had a higher and more significant odds ratio (2.6, 95% CI 1.2–5.3; p = 0.005) for developing TE complications than moderate parenchymal disease (0.9, 95% CI 0.5–1.8; p = 0.9). Patients with hypertension had the higher odds ratio (3.2; 95% CI 1.5–5.7; p < 0.001) for developing TE complications followed by BMI > 30 kg/m² with an odds ratio of 2.9 (95% CI 1.5–5.7; p = 0.001) and history of smoking with an odds ratio of 2.7 (95% CI 1.4–5.3; p = 0.003). The odds ratio of comorbidities and pulmonary parenchymal disease severity is listed in Table 3.

**Discussion**

Our study population had tested positive for COVID-19, and they were suspected of having thromboembolic complications; 53 patients (31%) had positive radiological findings supporting this diagnosis. We used the CT-SS developed by Yang et al. [14] to describe the degree of pulmonary parenchymal involvement. We noticed that severe disease among the TE group was significantly higher compared to the non-TE group and severe parenchymal disease had a higher and more significant odds ratio for developing TE complications. These data confirm that both pulmonary inflammation and thromboembolic complications of COVID-19 cannot be discussed separately.

Deteriorated CT-SS was expressed implicitly in literature discussing the effect of thromboembolic events on the clinical condition of COVID-19 illness, as most of those patients were critically ill or even admitted to the ICU. However, few studies have evaluated parenchymal lung injuries using a clear scoring system to classify pulmonary lesions. In this study, the mean CT-SS for the TE-positive group was 22.8 ± 11.4 vs. 17.6 ± 10.7 for the TE-negative group. Similar findings were reported by Espallargas et al. [16], who examined the CTPA for 47 patients and quantified parenchymal patterns using a score from 1 to 4. According to the severity scoring of the patients, they had 29 (61.7%) severe cases and concluded that significantly high pulmonary parenchymal scores were detected in severely ill COVID-19 patients suffering from PE. In contrary to these findings, Fang et al. [17] concluded that the radiological severity does not differ in subgroups of patients with or
without PE. They classified their patients according to the CT findings into mild (3/93), moderate (30/93), and severe (59/93). Pulmonary microangiopathy and coagulopathy and their relation to COVID-19 have also been investigated by Patel et al., who used Murray’s lung injury score to classify the disease severity in 39 mechanically ventilated patients. The mean CT extent of GGO and dense parenchymal opacifications were 36.3% and 42.7%. In addition, signs of pulmonary angiopathy in the form of dilated peripheral vessels and parenchymal perfusion defects were detected in 21/33 and 18/20 patients. Finally, they concluded that increasing pulmonary dead spaces and parenchymal opacification are strongly correlated by all means with pulmonary hypoperfusion in severely ill COVID-19 patients [18].

In this study, we focused on the identification of comorbidities raising the incidence of COVID-19-associated coagulopathy. Regarding different risk factors affecting those patients, the BMI > 30 kg/m² was statistically more frequent among the TE group than the non-TE group. Many studies proposed similar results, and now it is nearly established that obesity and elevated BMI are among the major risk factors for developing severe COVID-19 illness with all its serious complications [19, 20]. Similarly, smoking and hypertension were also statistically more frequent in TE compared to the non-TE group. These factors induce a hypercoagulable state by changing hemostasis, platelet aggregation, and induction of vascular endothelial damage that certainly worsens the general condition of the patients, especially in the presence of heavy viral loads [9, 21]. Dyslipidemia is a serious risk factor for cardiovascular disease. Nevertheless, our results showed that dyslipidemia was statistically more in the non-TE group than the TE group as most of the COVID-19 dyslipidemic patients were on statin therapy and consequently less vulnerable to develop TE. These results are consistent with the increasing number of studies reporting that dyslipidemic patients benefit from the protective effect of statins against TE events [22, 23]. Although several investigations have suggested that chronic illnesses such as DM, CKD, and pre-existing malignancy are implicated in COVID-19 pathogenesis and complications, we did not find a significant difference between our two study groups regarding these comorbidities [24, 25].

The incidence of ICU admission and mortality rates in this study were statistically more common among the TE group, and this undoubtedly resulted from the negative reciprocal relation between COVID-19 and TE injuries leading to more clinical deterioration. These results were consistent with studies carried out by Klok et al. [26]. Moreover, Roncon et al. [27] suggested that the actual number of ICU patients developing TE complications is underestimated as CTPA was only done for a selected number of patients because of the difficulties in its performance in mechanically ventilated patients. Consequently, the possibility of

Fig. 8 Splenic infarction ischemia in a 53-year-old male patient with confirmed diagnosis of COVID-19. a Coronal chest CT in pulmonary window shows mixed GGOs and consolidations in both lungs, CT-SS=27. b Axial CECT of the abdomen shows splenic infarctions. c Coronal CTA shows partially thrombosed splenic and hepatic arteries.
missed PE among hospitalized patients is highly probable, which explains a large number of deaths among COVID-19 patients. The coagulation disorders were also described during the previous coronaviruses’ outbreaks, but the incidence is remarkably higher with SARS-COV-2 [28, 29].

The history of TE disease had always been a major risk factor for recurrent thrombosis; however, it seemed that this allegation did not work for COVID-19. There was no significant difference between both groups concerning the presence of co-existing DVT or PE in this study. These results are consistent with Roncon et al. [27]. One of this study’s drawbacks is that we did not perform Doppler studies to assess the presence of co-existing DVT. The high incidence of PE in critically ill COVID-19 patients had directed many researchers to check the presence of DVT to investigate the source of clots, whether it is primarily originating from the pulmonary interstitial and alveolar damage or secondary to lower limb DVT [30].

In our study population, patients clinically suspected of pulmonary embolism were referred to perform a D-dimer test and CT pulmonary angiography. In PE-positive patients, the D-dimer level was significantly elevated compared to the patients with negative CTA. Our study agrees with Poyiadji et al. [23], who described high D-dimer levels in the patients with PE-positive group relative to those with negative PE (9.33 μg/ml vs. 2.54 μg/ml). Despite the large number of studies that have been conducted, there is still some argument about the definite cutoff value of D-dimer associated with a greater risk of mortality and severe illness [31, 32].

In our study, the distribution of pulmonary emboli favored more peripheral location (segmental and sub-segmental involvement represents 61.1%). These results are in agreement with previous reports [33–35] who described similar distribution in COVID-19 patients, which certainly differs from other non-COVID-19 patients and supports the theory of thrombo-inflammatory processes.

The novel coronavirus has a neurotrophic effect resembling other viruses leading to encephalitis and neuropathy. Nevertheless, this time, the unexpected shift in viral behavior was the increasing number of stroke cases [36]. In this study, 12 patients were diagnosed with ischemic stroke and 3 were diagnosed with dural sinus thrombosis. Mao et al. [37] discussed neurological manifestations of COVID-19 and reported 36.4% for

### Table 2 Chest CT-SS and incidence of imaging features in both groups

| Disease severity by CT-SS | Pulmonary embolism (n=102) | Cerebral ischemia (n=33) | Abdominal ischemia (n=30) | Peripheral ischemia (n=6) | p-value |
|---------------------------|----------------------------|-------------------------|--------------------------|-------------------------|--------|
| Mild (n=53)               | + ve: 4 (n=24)             | + ve: 4 (n=15)          | + ve: 2 (n=8)            | + ve: 1 (n=4)          | 0.04*  |
|                          | - ve: 31 (n=78)            | - ve: 4 (n=18)          | - ve: 14 (n=22)          | - ve: 2 (n=2)          | 0.9    |
| Moderate (n=66)           | + ve: 8 (n=27)             | + ve: 4 (n=15)          | + ve: 4 (n=22)           | + ve: 2 (n=2)          | 0.04*  |
|                          | - ve: 27 (n=72)            | - ve: 4 (n=18)          | - ve: 14 (n=22)          | - ve: 2 (n=2)          | 0.9    |
| Sever (n=52)              | + ve: 12 (n=20)            | + ve: 4 (n=18)          | + ve: 4 (n=22)           | + ve: 1 (n=2)          | 0.04*  |
|                          | - ve: 20 (n=78)            | - ve: 4 (n=18)          | - ve: 14 (n=22)          | - ve: 2 (n=2)          | 0.9    |

CT features:
- GGO(n=136) 20 65 11 14 6 14 4 2 0.6
- Consolidation(n=81) 17 36 6 8 4 7 2 1 0.7
- Crazy paving(n=40) 14 14 4 2 2 3 1 0 0.03*
- Reversed halo(n=13) 4 5 2 1 0 1 0 0 0.4
- Subpleural bands (n=44) 9 18 5 5 2 3 1 1 0.6
- Bronchiectasis(n=42) 9 19 5 5 2 3 1 1 0.4
- Nodules(n=4) 1 2 1 0 0 0 0 0 0.6
- Lymphadenopathy(n=10) 2 3 2 1 1 0 0 1 0.3
- Pleural effusion(n=18) 6 6 2 1 1 2 1 0 0.2

*-Significant results

### Table 3 Odds ratio and confidence intervals of comorbidities and parenchymal disease severity to develop thromboembolic complications

| Variable               | Odds ratio | 95% CI      | p-value |
|------------------------|------------|-------------|---------|
| Gender (male)          | 0.8        | 0.4–1.5     | 0.8     |
| BMI > 30               | 2.9        | 1.5–5.7     | 0.001*  |
| Smoking                | 2.7        | 1.4–5.3     | 0.003*  |
| HTN                    | 3.2        | 1.6–6.3     | <0.001* |
| DM                     | 1.2        | 0.6–2.4     | 0.5     |
| Previous PE/DVT        | 1.3        | 0.5–3.6     | 0.5     |
| Dyslipidemia           | 0.4        | 0.2–0.8     | 0.01    |
| CKD                    | 0.3        | 0.1–0.7     | 0.006   |
| Malignancy             | 0.7        | 0.2–2.3     | 0.6     |
| Parenchymal disease severity |         |             |         |
| - Mild disease         | 0.3        | 0.1–0.8     | 0.009*  |
| - Moderate disease     | 0.9        | 0.5–1.8     | 0.9     |
| - Severe disease       | 2.6        | 1.3–5.3     | 0.005*  |

*-Significant results

© Springer
neurologic symptoms and 5.7% for acute cerebrovascular disease. Belani et al. [38] reported a 46.3% stroke incidence among COVID-19-positive patients compared to the non-COVID-19 control group. Large vessel occlusion had the highest incidence among stroke patients in this study; interestingly, this was in line with other studies carried out by Beyrouti et al. [39] and Avula et al. [40]. Other stroke phenotypes included infarctions in multiple sites. These findings are also consistent with Tan et al. [41] conducted a meta-analysis of the neuroimaging data of published 103 cases, and they reported that most of the cerebral stroke was large vessel occlusion (62.1%), followed by multiple vascular occlusion (26.2%).

The incidence of COVID-19 patients presenting with gastrointestinal symptoms is about 10%, and these symptoms are rarely related to acute mesenteric ischemia [42, 43]. We had seven patients diagnosed with variable degrees of mesenteric artery occlusion and signs of AMI, including edematous dilated intestinal loops and absence of intestinal wall enhancement. Two case studies carried out by Fan [44] and Cheung et al. [45] described cases of AMI with no significant predisposing factors for TE events. In our study, we also had one patient who presented with partial splenic artery thrombosis and subsequent splenic infarctions. The described cases of splenic involvement by COVID-19 in literature are rare, with no definite reported incidence [46].

The association between peripheral arterial thrombosis and COVID-19 infection has been reported. Goldman et al. [47] reported a significant thrombus burden and a high frequency of thromboses involving proximal vessels associated with COVID-19. One patient in this study presented with extensive thrombosis of the abdominal aorta and both lower limb arteries. COVID-19 may predispose to disseminated intravascular coagulopathy as we encountered thromboembolic complications in multiple locations in three patients. Besutti et al. [48] report combined visceral infarctions with splenic and renal infarctions, while Azouz et al. [49] described AMI in association with MCA occlusion and a free-floating aortic thrombus.

This study has few limitations that should be addressed. The existence of additional entities such as neurogenic pulmonary edema in stroke patients or frequently seen aspiration in intubated patients might overestimate the severity scoring. They are non-COVID clinical contributors to disease severity and challenging to differentiate from pre-existing parenchymal changes secondary to COVID-19. Most of the study data was driven from PE-related parenchymal disease with relatively low sample numbers of non-PE-related parenchymal disease. A further large-scale study with a separate analysis for PE and non-PE thromboembolic complications is needed.

Conclusion

The present data suggests that thromboembolic complications can be correlated with the severity of the pulmonary parenchymal disease. Therefore, both pulmonary and thromboembolic complications of COVID-19 cannot be discussed separately, especially when TE complications add much burden to the clinical condition of COVID-19 patients leading to further deterioration.

Author contribution All authors have contributed, read, and approved the manuscript.

Data availability All data generated during this study are included in this published article.

Declarations

Ethics approval and consent to participate Institutional Review Board approved this study.

Consent for publication The authors hereby transfer, assign, or otherwise convey all copyright ownership to the Emergency Radiology journal in the event that such work is published in that Journal.

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Hui DS, Azhar EI, Madani TA et al (2020) The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 91:264–266
2. WHO. Noval coronavirus Feb 11, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2
3. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J et al (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395(10223):514–23
4. Zhu N, Zhang D, Wang W (2020) China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China. N Engl J Med 382(8):727–733
5. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A et al (2013) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13(9):752–761
Lec N, Hui D, Wu A, Chan P, Cameron P, Joynt GM et al (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348(20):1986–1994

7. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastiani T et al (2020) Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan. Italy Thromb Res 191:9–14

8. Vernuccio F, Lombardo FP, Cannella R et al (2020) Thromboembolic complications of COVID-19: the combined effect of a pro-coagulant pattern and an endothelial thrombo-inflammatory syndrome. Clin Radiol 75(11):804–810

9. Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood J Am Soc Hematol 135(23):2033–2040

10. Llitjos JF, Leclerc M, Chochois C et al (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 18:1743–1746

11. Kruse JM, Magomedov A, Kurreck A, Münch FH, Koerner R, Kamhieh-Milz J, Kahl A, Gothardt I, Piper SK, Eckardt KU, Dörner T, Zickler D (2020) Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care 24(1):676

12. Elmokadem AH, Bayoumi NT, Gadelhak BN, Abdel-Wahab RM, Zaky M et al (2021) Mimickers of novel coronavirus disease 2019 (COVID-19) on chest CT: spectrum of CT and clinical features. Insights Imaging [Internet];12(1):12. Available from: https://doi.org/10.1186/s13244-020-00956-6

13. Elmokadem AH, Bayoumi D, Abo-Hedibah SA, El-Morsy A (2021) Diagnostic performance of chest CT in differentiating COVID-19 from other causes of ground-glass opacities. Egypt J Radiol Nucl Med 52(1):1–10

14. Yang R, Li X, Liu H, Zhen Y, Zhang X, Xiong Q et al (2020) Chest CT severity score: an imaging tool for assessing severe COVID-19. Radiol Cardiothorac Imaging 2(2):e200047

15. Abo-Hedibah SA, Tharwat N, Elmokadem AH (2021) Is chest X-ray severity scoring for COVID-19 pneumonia reliable? Pol J Radiol 86:e432–e439

16. Espallargas I, Sevilla JIR, Chiariadá DAR, Salar A, Casamayor G, Villar-Garcia J et al (2021) CT imaging of pulmonary embolism in patients with COVID-19 pneumonia: a retrospective analysis. Eur Radiol 31(4):1915–1922

17. Fang C, Garzillo G, Batoi B, Teo J, Berovic M, Sidhu P et al (2020) Extent of pulmonary thromboembolic disease in patients with COVID-19 on CT: relationship with pulmonary parenchymal disease. Clin Radiol 75(10):780–788

18. Patel BV, Arachchilage DJ, Ridge CA, Bianchi P, Doyle JF, Garﬁeld B et al (2020) Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med 202(5):690–699

19. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q et al (2020) Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes care 43(7):1392–1398

20. Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND (2020) COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 46(7):763–771

21. Llitjos JF, Leclerc M, Chochois C et al (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 18(7):1743–1746

22. Mestre-Gómez B, Lorente-Ramos RM, Rogado J et al (2021) Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis 51(1):40–46

23. Poyiadji N, Cormier P, Patel PY, Hadied MO, Bhargava P, Khanna K, Nadig J, Keimg J, Spizarny D, Reeser N, Klochko C, Peterson EL, Song T (2020) Acute pulmonary embolism and COVID-19. Radiology 297(3):E335–E338. https://doi.org/10.1148/radiol.2020201955

24. Myers LC, Parodi SM, Escobar GJ, Liu VX (2020) Characteristics of hospitalized adults with COVID-19 in an integrated health care system in California. JAMA 323(21):2195–2198

25. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G (2020) Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med 9(5):1417. https://doi.org/10.3390/jcm9051417

26. Klokk FA, Krup M, van der Meer NJM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-27. Roncon L, Zuin M, Barco S, Valerio L, Zuliani G, Zonzi P et al (2020) Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis. Eur J Intern Med 82:29–37

28. Giannis D, Zogas IA, Gianni P (2020) Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 127:104362

29. Chen J, Wang X, Zhang S, Lin B, Wu X, Wang Y et al (2020) Characteristics of acute pulmonary embolism in patients with COVID-19 associated pneumonia from the city of Wuhan. Clin Appl Thromb Hemost 26:1076029620936772

30. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macias M, Toledo-Samaniego N et al (2020) Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res 192:23–26

31. Naymagon L, Zubizarreta N, Feld J, van Gerwen M, Alsen M, Thibaud S et al (2020) Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19. Thromb Res 196:99–105

32. Price LC, McCabe C, Garﬁeld B, Wort SJ (2020) Thrombosis and COVID-19 pneumonia: the clot thickens! Eur Respir J 56(1):2001608

33. Bompard F, Monnier H, Saib I, Tordjman M, Abdoul H, Fournier L, Sanchez O, Lorut C, Chassagnon G, Revel MP (2020) Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 56(1):2001365. https://doi.org/10.1183/13993903.01365-2020

34. van Dam LF, Kroft LJMJ, van der Wal LI, Carne ﬂgier SC, Eikenboom J, de Jonge E et al (2020) Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Thromb Res 193:86–89

35. Mueller-Peltzer K, Krauss T, Benndorf M, Lang CN, Bamberg F, Bode C et al (2020) Pulmonary artery thrombi are co-located with opacifications in SARS-CoV2 induced ARDS. Respir Med 172:106135

36. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh JP et al (2020) Large-vein stroke as a presenting feature of COVID-19 in the young. N Engl J Med 382(20):e60

37. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):683–690

38. Belani P, Schefflein J, Khaira S, Rigney B, Delman BN, Mahmodi K et al (2020) COVID-19 is an independent risk factor for acute ischemic stroke. AJNR Am J Neuroradiol 41(8):1361–1364

39. Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY et al (2020) Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry 91(8):889–891

40. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S et al (2020) COVID-19 presenting as stroke. Brain Behav Immun 87:115–119

41. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES et al (2020) COVID-19 and ischemic stroke: a systematic review
and meta-summary of the literature. J Thromb Thrombolysis 50(3):587–595

42. Norsa L, Valle C, Morotti D, Bonaffini PA, Indriolo A, Sonzogni A (2020) Intestinal ischemia in the COVID-19 era. Dig Liver Dis 52(10):1090–1091

43. Parry AH, Wani AH, Yaseen M (2020) Acute mesenteric ischemia in severe coronavirus-19 (COVID-19): possible mechanisms and diagnostic pathway. Acad Radiol 27(8):1190

44. Fan BE (2020) COVID-19-associated thromboembolic events causing acute mesenteric ischaemia. Acad Radiol 27(12):1788–1789

45. Cheung S, Quiw JC, Pillai A, Onwu C, Tharayil ZJ, Gupta R (2020) Superior mesenteric artery thrombosis and acute intestinal ischemia as a consequence of COVID-19 infection. Am J Case Rep 21:e925753

46. Santos Leite Pessoa M, Franco Costa Lima C, Farias Pimentel AC, Godeiro Costa JC, Bezerra Holanda JL (2020) Multisystemic infarctions in COVID-19: focus on the spleen. Eur J Case Rep Intern Med 7(7):001747

47. Goldman IA, Ye K, Scheinfeld MH (2020) Lower-extremity arterial thrombosis associated with COVID-19 is characterized by greater thrombus burden and increased rate of amputation and death. Radiology 297(2):E263–E269

48. Besutti G, Bonacini R, Iotti V, Marini G, Riva N, Dolci G et al (2020) Abdominal visceral infarction in 3 patients with COVID-19. Emerg Infect Dis 26(8):1926–1928

49. Azouz E, Yang S, Monnier-Cholley L, Arrivé L (2020) Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19. Intensive Care Med 46(7):1464–1465

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.